SS Innovations International, Inc. — fact timeline

SS Innovations International, Inc. entered into Sales Agreement with Virtu Americas LLC valued at up to $50 million (effective 2026-06-18).

“On June 18, 2026, the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”), to sell shares of its common stock, par value $0.0001 per share (the “Common Stock”), for an aggregate offering price of up to $50 million (the “Shares”) from time to time, through an “at the market offering” (the “ATM Offering”) program under which Virtu will act as an exclusive sales agent or principal.”

Milan Rao departed as Global Chief Operating Officer and Chief Financial Officer at SS Innovations International, Inc..

“On May 18, 2026, Milan Rao informed the Company that he would step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.”

SS Innovations International, Inc. reported the three months ended March 31, 2026 results: revenue $11.1 million, EPS $(0.02) per diluted share.

“Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 Overview ● Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. ● Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. ● Gross profit rose 390.0% to $5.3 million from $1.1”

SS Innovations International, Inc. reported the twelve months ended December 31, 2025 results: revenue $42.5 million, net income $12.1 million, EPS $(0.06) per diluted share.

“Full Year 2025 Overview ● Revenue increased 105.7% to $42.5 million from $20.6 million in 2024. ● Gross margin expanded to 46.0% from 40.9% in 2024. ● Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024. ● Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024.”

SS Innovations International, Inc. reported the three months ended December 31, 2025 results: revenue $14.5 million, net income $2.5 million, EPS $(0.01) per diluted share.

“Fourth Quarter 2025 Overview ● Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. ● Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. ● Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024. ● Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024.”

SS Innovations International, Inc. issued warrants to purchase 41,667 shares of our common stock of warrant to a FINRA member firm for exercise price of $3.45 per share.

“the Company will pay a FINRA member firm a cash commission of $175,000 (7% of the investment) and issue to such firm five-year warrants to purchase 41,667 shares of our common stock at an exercise price of $3.45 per share”

SS Innovations International, Inc. issued 4,474,833 shares of common stock of common stock to existing and new investors, led by Manipal Global Health Services for at $3.00 per share for a total of approximately $13.4 million.

“an aggregate of 4,474,833 shares of common stock at $3.00 per share for a total of approximately $13.4 million, to existing and new investors, led by Manipal Global Health Services”

SS Innovations International, Inc. issued 1,300,006 shares of common stock to Dr. Sudhir Srivastava, Dr. Frederic Moll, and Tim Adams for at an average price of $4.00 per share for a total of approximately $5.2 million.

“an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share for a total of approximately $5.2 million, to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer (498,753 shares at $4.01 per share for a total of $2.0 million), Dr. Frederic Moll, our Vice Chairman (501,253 shares at $3.99 per share for a total of $2.0 million), and Tim Adams, a director (300,000 shares at $3.99 per share for a total of $1.2 million)”

Dr. Vishwajyoti P. Srivastava was appointed as Chief Executive Officer – Asia Pacific at SS Innovations International, Inc..

“On May 21, 2025, our board of directors appointed Dr. Vishwajyoti P. Srivastava, M.D., who has served as our President and Chief Operating Officer – Asia, to the new position of Chief Executive Officer – Asia Pacific.”

Arvind Palaniappan was appointed as Interim Chief Financial Officer at SS Innovations International, Inc..

“Arvind Palaniappan joined the Company as its Interim Chief Financial Officer, effective May 1, 2025”

Anup Sethi departed as Chief Financial Officer at SS Innovations International, Inc..

“Anup Sethi stepped down as the Company’s Chief Financial Officer effective April 30, 2025”

Timothy P. Adams was appointed as Director at SS Innovations International, Inc..

“Effective August 20, 2024, SSi expanded its board of directors from five (5) to seven (7) members and Dr. Frederic Moll and Timothy P. Adams were appointed as directors to fill the newly created vacancies on the board.”

Dr. Frederic Moll was appointed as Director and Non-executive Vice Chairman at SS Innovations International, Inc..

“Effective August 20, 2024, SSi expanded its board of directors from five (5) to seven (7) members and Dr. Frederic Moll and Timothy P. Adams were appointed as directors to fill the newly created vacancies on the board. In addition, Dr. Moll was appointed as non-executive Vice Chairman of the Board of Directors.”

SS Innovations International, Inc. dismissed BF Borgers CPA PC as its auditor.

“Effective May 13, 2024, the Company dismissed BF Borgers CPA PC (" Borgers ") as its independent registered public accounting firm.”

Prof. Dr. Somashekhar S.P. was appointed as Director at SS Innovations International, Inc..

“Effective July 30, 2023, SSII expanded its board of directors to five (5) members and Dr. Mylswamy Annadurai and Prof. Dr. Somashekhar S.P. were appointed directors to fill the newly created vacancies on the board.”

Dr. Mylswamy Annadurai was appointed as Director at SS Innovations International, Inc..

“Effective July 30, 2023, SSII expanded its board of directors to five (5) members and Dr. Mylswamy Annadurai and Prof. Dr. Somashekhar S.P. were appointed directors to fill the newly created vacancies on the board.”

SS Innovations International, Inc. underwent a change of control involving CardioVentures, Inc. for 135,808,884 shares of SSII common stock and shares of Series A Non-Convertible Preferred Stock (closed 2023-04-14).

“Based in Haryana, common stock of CardioVentures (including certain parties who provided interim convertible financing during the pendency of the Merger Agreement, were issued 135,808,884 shares of SSII common stock, representing approximately 95% of issued and outstanding shares of SSII common stock post-Merger, with the existing shareholders of SSII holding”

SS Innovations International, Inc. completed an acquisition involving CardioVentures, Inc. for Holders of CardioVentures common stock were issued 135,808,884 shares of SSII common stock (approximately 95% of post-Merger shares) and shares of newly designa (closed 2023-04-14).

“shares of common stock of CardioVentures (including certain parties who provided interim convertible financing during the pendency of the Merger Agreement, were issued 135,808,884 shares of SSII common stock, representing approximately 95% of issued and outstanding shares of SSII common stock post-Merger, with the existing shareholders of SSII holding”

SS Innovations International, Inc. entered into Investment Agreement with Dr. Frederic Moll valued at $1,000,000 in financing (effective 2023-04-07).

“On April 7, 2023, we entered into an Investment Agreement (the “ Investment Agreement ”) with Dr. Frederic Moll (“ Dr. Moll ”), pursuant to which, on April 10, 2023, Dr. Moll, in addition to $2,000,000 in financing previously provided to the Company (the “ Initial Investment ”), provided us with an additional $1,000,000 in financing (the “ Additional Investment ,” and together with the Initial Investment, the “ Interim Financing ”)”

SS Innovations International, Inc. entered into Merger Agreement with CardioVentures, Inc. and Dr. Sudhir Srivastava (effective 2022-11-07).

“On November 7, 2022, AVRA entered into a definitive Merger Agreement (the “ Merger Agreement ”), by and among AVRA, AVRA-SSI Merger Corporation, a Delaware corporation and wholly-owned subsidiary of AVRA (“ Merger Sub ”), CardioVentures, Inc., a Delaware corporation (“ SSI - DE ”) Dr. Sudhir Srivastava (“ Dr. Srivastava ”), who, through his holding company, owns a controlling interest in SSI-DE.”